Jefferies Reiterates Buy on Oracle (ORCL) Folowing 2Q Report
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Drexel Hamilton Reiterates Buy on Oracle (ORCL) Following 2Q Report
December 16, 2016 9:27 AM ESTDrexel Hamilton reiterated a Buy rating and $47.00 price target on Oracle (NYSE: ORCL) following the company's 2Q earnings report. Oracle reported sales of $9.07 billion, which missed the Street's $9.11 billion estimate. Pro forma EPS of $0.61 met the consensus estimate at $0.60.
Analyst Brian White... More
Wedbush Raises Price Target on Oracle (ORCL) Following 2Q Report
December 16, 2016 8:56 AM ESTWedbush reiterated a Neutral rating on Oracle (NYSE: ORCL), and raised the price target to $42.00 (from $41.00), following the company's 2Q earnings report. revenues were roughly in line with consensus and EPS were at the top of the range. However, cloud bookings grew only 30% Y/Y (down from 39% last quarter),... More
Options expected to have Increasing volume: YHOO ORCL ADBE
December 16, 2016 5:42 AM ESTOptions expected to have Increasing volume: YHOO ORCL ADBE
... MoreAfter-Hours Stock Movers 12/15: (JBL) (MRK) Higher; (AGIO) (FNSR) (ORCL) Lower (more...)
December 15, 2016 6:10 PM ESTToday's After-Hours
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) 19.6% LOWER; announced that it is no longer developing its second pyruvate kinase-R (PKR) activator, AG-519, and withdrew its investigational new drug (IND) application yesterday following a verbal notification of a clinical hold from the U.S. Food and Drug Administration (FDA). These decisions do not affect the Companys ongoing global Phase 2 study... More
Oracle (ORCL) Offers Q3 Guidance
December 15, 2016 5:21 PM ESTOracle (NYSE: ORCL) sees Q3 adjusted EPS in constant currency of $0.61-$0.64 vs the consensus of $0.64. Revenue is seen up 3%-5% in constant currency.
Oracle (ORCL) Tops Q2 EPS by 1c
December 15, 2016 4:00 PM ESTOracle (NYSE: ORCL) reported Q2 EPS of $0.61, $0.01 better than the analyst estimate of $0.60. Revenue for the quarter came in at $9.07 billion versus the consensus estimate of $9.12 billion.
"For four consecutive quarters our Cloud SaaS & PaaS revenue growth rate has increased," said Oracle CEO, Safra Catz. "As we get bigger in the cloud, we grow faster in the cloud. Our non-GAAP constant currency SaaS and PaaS growth rate... More
Oracle (ORCL) December 40.50 straddle priced for movement of 3.4% into Q2
December 15, 2016 2:44 PM ESTOracle (NYSE: ORCL) December 40.50 straddle priced for movement of 3.4% into Q2
... MoreOracle (ORCL) December volatility at elevated at 85 into Q2
December 15, 2016 12:59 PM ESTOracle (NYSE: ORCL) December call option implied volatility is at 87, December is at 37; January is at 23; compared to its 52-week range of 14 to 34 into the expected release Q2 results today.
... More
